YM BioSciences (YM.TO) Announces $14.05 Million Offer for Cytopia Limited (CYT.AX), an Australian Cancer-Focused Development Company
10/6/2009 6:49:53 AM
More...
|
Cytopia Limited (CYT.AX)'s CYT387 Receives FDA Clearance to Start US Clinical Trials
9/4/2009 8:36:13 AM
More...
|
Cytopia Limited (CYT.AX) Lodges IND for JAK2 Inhibitor CYT387
6/23/2009 8:58:46 AM
More...
|
Cytopia Limited (CYT.AX): Oral VDA CYT997 - Phase I Clinical Trial Presentation at American Society of Clinical Oncology
5/29/2009 10:47:06 AM
More...
|
Cytopia Limited (CYT.AX) Presentation on VDA CYT997 at American Association for Cancer Research Conference
4/16/2009 11:32:28 AM
More...
|
Cytopia Limited (CYT.AX) Letter to Progen Industries Limited (PGLA) Shareholders
2/25/2009 9:50:08 AM
More...
|
Cytopia Limited (CYT.AX) and Other Progen Pharmaceuticals Limited (PGLA) Shareholders Maintain Call for Meeting
2/9/2009 8:30:37 AM
More...
|
Cytopia Limited (CYT.AX) Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997
2/5/2009 10:51:26 AM
More...
|
Cytopia Limited (CYT.AX) Release: Progen Pharmaceuticals Limited (PGLA) Shareholders Call Meeting to Spill Progen Board and Offer Merger or Full Cash Back to Shareholders
1/29/2009 11:51:03 AM
More...
|
Presentation on Cytopia Limited (CYT.AX)'s JAK2 Inhibitor Program in Myeloproliferative Disorders
12/8/2008 8:06:06 AM
More...
|
|